Under the terms
of the Schrödinger partnership, Nimbus has exclusive access to an evergreen
list of 20 targets.
- This allows Nimbus to retain a continuous lock on the
most valuable targets in inflammation, anti-infectives, cardiovascular disease,
fibrosis, oncology including cancer metabolism, neuropathic pain, COPD and
other lung diseases, and Parkinson’s.